UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________

FORM 8-K

_______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 9, 2012

_______________

HELIX BIOMEDIX, INC.

(Exact name of registrant as specified in its charter)

_______________


DELAWARE	033-20897-D	91-2099117
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)

22118 20th Avenue S.E., Suite 204

Bothell, Washington 98021

(425) 402-8400

(Address and telephone number of registrant’s principal executive offices)

_______________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01

Entry into a Material Definitive Agreement.

On April 9, 2012, Helix BioMedix, Inc. (the “Company”) entered into a Third Amendment (the “Amendment”) with Camden Street Partners, LLC (“Camden”) and NuGlow Cosmaceuticals, LLC (“NuGlow LLC”), pursuant to which the parties agreed to amend that certain Amended and Restated Operating Agreement of NuGlow Cosmaceuticals, LLC dated as of July 1, 2010, as amended (the “NuGlow LLC Operating Agreement”), to provide for the allocation and distribution of $27,000 and $63,000 in additional capital contributions in NuGlow LLC contemporaneously made by the Company and Camden, respectively, prior to other allocations or distributions thereunder.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		HELIX BIOMEDIX, INC.

Dated: April 12, 2012	By:	/s/ R. Stephen Beatty
		R. Stephen Beatty
		President and Chief Executive Officer

HELIX BIOMEDIX INC 8-K